3,5-Dinitrobenzylsulfanyl tetrazoles and 1,3,4-oxadiazoles, previously identified as having high in vitro activities against both replicating and nonreplicating mycobacteria and favorable cytotoxicity and genotoxicity profiles were investigated. First we demonstrated that these compounds act in a deazaflavin-dependent nitroreduction pathway and thus require a nitro group for their activity. Second, we confirmed the necessity of both nitro groups for antimycobacterial activity through extensive structure-activity relationship studies using 32 structural types of analogues, each in a five-membered series. Only the analogues with shifted nitro groups, namely, 2,5-dinitrobenzylsulfanyl oxadiazoles and tetrazoles, maintained high antimycobacterial activity but in this case mainly as a result of DprE1 inhibition. However, these analogues also showed increased toxicity to the mammalian cell line. Thus, both nitro groups in 3,5-dinitrobenzylsulfanyl-containing antimycobacterial agents remain essential for their high efficacy, and further efforts should be directed at finding ways to address the possible toxicity and solubility issues, for example, by targeted delivery.

Charles University Faculty of Pharmacy in Hradec Králové Akademika Heyrovského 1203 50005 Hradec Králové Czech Republic

Faculty of Natural Sciences Department of Biochemistry Comenius University in Bratislava Ilkovičova 6 Mlynská dolina 842 15 Bratislava Slovakia

Global Health Institute École Polytechnique Fédérale de Lausanne 1015 Lausanne Switzerland

Regional Institute of Public Health Department of Bacteriology and Mycology Partyzánské náměstí 7 70200 Ostrava Czech Republic

Univ Lille CNRS Inserm CHU Lille Institut Pasteur de Lille U1019 UMR 9017 CIIL Center for Infection and Immunity of Lille F 59000 Lille France

000      

00000naa a2200000 a 4500

001      

bmc24007598

003      

CZ-PrNML

005      

20240423160119.0

007      

ta

008      

240412s2024 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1021/acs.jmedchem.3c00925 $2 doi

035    __

$a (PubMed)38157261

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Karabanovich, Galina $u Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic

245    10

$a Both Nitro Groups Are Essential for High Antitubercular Activity of 3,5-Dinitrobenzylsulfanyl Tetrazoles and 1,3,4-Oxadiazoles through the Deazaflavin-Dependent Nitroreductase Activation Pathway / $c G. Karabanovich, V. Fabiánová, A. Vocat, J. Dušek, L. Valášková, J. Stolaříková, RRA. Kitson, P. Pávek, K. Vávrová, K. Djaout, K. Mikušová, AR. Baulard, ST. Cole, J. Korduláková, J. Roh

520    9_

$a 3,5-Dinitrobenzylsulfanyl tetrazoles and 1,3,4-oxadiazoles, previously identified as having high in vitro activities against both replicating and nonreplicating mycobacteria and favorable cytotoxicity and genotoxicity profiles were investigated. First we demonstrated that these compounds act in a deazaflavin-dependent nitroreduction pathway and thus require a nitro group for their activity. Second, we confirmed the necessity of both nitro groups for antimycobacterial activity through extensive structure-activity relationship studies using 32 structural types of analogues, each in a five-membered series. Only the analogues with shifted nitro groups, namely, 2,5-dinitrobenzylsulfanyl oxadiazoles and tetrazoles, maintained high antimycobacterial activity but in this case mainly as a result of DprE1 inhibition. However, these analogues also showed increased toxicity to the mammalian cell line. Thus, both nitro groups in 3,5-dinitrobenzylsulfanyl-containing antimycobacterial agents remain essential for their high efficacy, and further efforts should be directed at finding ways to address the possible toxicity and solubility issues, for example, by targeted delivery.

650    _2

$a zvířata $7 D000818

650    12

$a Mycobacterium tuberculosis $7 D009169

650    _2

$a oxadiazoly $x farmakologie $x chemie $7 D010069

650    _2

$a tetrazoly $x farmakologie $x chemie $7 D013777

650    _2

$a mikrobiální testy citlivosti $7 D008826

650    _2

$a antituberkulotika $x farmakologie $x chemie $7 D000995

650    _2

$a vztahy mezi strukturou a aktivitou $7 D013329

650    _2

$a nitroreduktasy $7 D009601

650    _2

$a savci $7 D008322

655    _2

$a časopisecké články $7 D016428

700    1_

$a Fabiánová, Viktória $u Faculty of Natural Sciences, Department of Biochemistry, Comenius University in Bratislava, Ilkovičova 6, Mlynská dolina, 842 15 Bratislava, Slovakia

700    1_

$a Vocat, Anthony $u Global Health Institute, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland

700    1_

$a Dušek, Jan $u Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic

700    1_

$a Valášková, Lenka $u Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic

700    1_

$a Stolaříková, Jiřina $u Regional Institute of Public Health, Department of Bacteriology and Mycology, Partyzánské náměstí 7, 70200 Ostrava, Czech Republic

700    1_

$a Kitson, Russell R A $u Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic

700    1_

$a Pávek, Petr $u Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic

700    1_

$a Vávrová, Kateřina $u Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic

700    1_

$a Djaout, Kamel $u Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France

700    1_

$a Mikušová, Katarína $u Faculty of Natural Sciences, Department of Biochemistry, Comenius University in Bratislava, Ilkovičova 6, Mlynská dolina, 842 15 Bratislava, Slovakia

700    1_

$a Baulard, Alain R $u Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France

700    1_

$a Cole, Stewart T $u Global Health Institute, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland

700    1_

$a Korduláková, Jana $u Faculty of Natural Sciences, Department of Biochemistry, Comenius University in Bratislava, Ilkovičova 6, Mlynská dolina, 842 15 Bratislava, Slovakia

700    1_

$a Roh, Jaroslav $u Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic $1 https://orcid.org/0000000346988379

773    0_

$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 67, č. 1 (2024), s. 81-109

856    41

$u https://pubmed.ncbi.nlm.nih.gov/38157261 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240412 $b ABA008

991    __

$a 20240423160115 $b ABA008

999    __

$a ok $b bmc $g 2081538 $s 1217365

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2024 $b 67 $c 1 $d 81-109 $e 20231229 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049

LZP    __

$a Pubmed-20240412